Sign In
Free Newsletter
Noom acquires compounding pharmacy to expand health care services
Noom's acquisition of Tailor Made Compounding aims to help the company expand beyond weight loss into preventive health and healthy aging, adding personalized therapies and pharmacy capabilities.
Novo Nordisk, Hims & Hers settle GLP-1 drug dispute
The settlement between Novo Nordisk and Hims & Hers allows the telehealth platform to sell FDA-approved Wegovy and Ozempic GLP-1 drugs.
Hims & Hers pulls copycat Wegovy pill amid legal action
Hims & Hers stopped offering compounded GLP-1 semaglutide pills following a Novo Nordisk lawsuit and FDA concerns over copycat drugs.
Novo Nordisk ends Hims & Hers deal over Wegovy knockoffs
The conclusion of the collaboration comes as the drug maker cites illegal sales of compounded knockoff weight loss drugs and expresses growing concerns over patient safety.
Novo Nordisk expands Wegovy access as FDA bans semaglutide copies
The Swiss drugmaker – which has its U.S. headquarters in Plainsboro – is launching a series of initiatives to offer patients authentic versions of its blockbuster weight-loss treatment.
Trump drug pricing order draws NJ pharma industry backlash
Local industry leaders say the attempt to lower costs could harm innovation, threaten jobs and import failed foreign pricing models to U.S. markets.
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
If the administration signs off on the application, the company’s experimental once-daily version will become the first oral GLP-1 for weight loss.
Novo Nordisk scores court win against GLP-1 copycat compounders
A Texas court denied a request to allow continued sales of compounded Wegovy and Ozempic after the FDA ruled the semaglutide shortage has ended.
